Read this first
This is plain-language harm-reduction information, not medical advice. Peptides discussed here are research compounds; most are not approved for human use. People will use them either way — we would rather they have the facts.
On 1 April 2026 the US FDA approved Eli Lilly's orforglipron, sold as Foundayo, as a once-daily oral GLP-1 medicine for weight management. The approval is in adults with obesity, or with overweight and at least one weight-related condition, alongside a reduced-calorie diet and more physical activity.
What was reported
According to EMJ's report of the announcement (2 April 2026), prescriptions were accepted immediately and shipping began on 6 April. The dose starts at 0.8 mg once daily, and the medicine should not be combined with other GLP-1 products. In the ATTAIN-1 trial, EMJ reports that people on the highest dose lost on average more than 12 per cent of body weight versus about 1 per cent on placebo; among all participants who completed treatment, the average loss was above 10 per cent versus about 2 per cent on placebo. Lilly also reported improvements in waist circumference, non-HDL cholesterol, triglycerides and systolic blood pressure.
Lilly's chief executive David Ricks was quoted saying that fewer than one in ten people who could benefit from a GLP-1 are taking one, citing access and stigma barriers.
Why this is different
Most GLP-1 weight-loss drugs, including semaglutide and tirzepatide, are peptides given by injection. Orforglipron is a small-molecule drug that acts on the same receptor but is taken by mouth. That matters for harm reduction because the grey market for injectable peptides is driven partly by cost and access. A licensed oral option, if it is affordable and widely available, could reduce the pull toward unlicensed vials of unknown content.
Cautions
- An approval is not an endorsement for everyone. It applies to the population in the label and requires a prescription.
- The weight loss figures are averages from a trial and individual results vary. The 12 per cent figure applies to people who stayed on treatment at the highest dose.
- The EMJ report did not detail side effects, so check the prescribing information. As with other GLP-1 medicines, gastrointestinal effects are what prescribers usually discuss, but we have not confirmed rates from the sources we read.
- This is a US approval. We did not confirm a UK or EU decision.
Do not combine an approved GLP-1 with unlicensed GLP-1 or "research" peptides. The label itself says Foundayo should not be used with other GLP-1 agents.
What is still unknown
Long-term safety beyond the trials, real-world persistence, and how cost and supply will play out. Price details were not confirmed in the pages we were able to open, so we leave them out.
Common questions
Is orforglipron a peptide?
It is a small-molecule oral GLP-1 receptor agonist rather than an injectable peptide, according to coverage of its approval.